Nanogel-based scaffold delivery of prostaglandin E2 receptor-specific agonist in combination with a low dose of growth factor heals critical-size bone defects in mice

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 1021-1033

  Kamolratanakul, Paksinee ^a   Hayata, Tadayoshi ^a   Ezura, Yoichi ^a   Kawamata, Aya ^a   Hayashi, Chikako ^a   Yamamoto, Yuka ^a   Hemmi, Hiroaki ^a   Nagao, Masashi ^a   Hanyu, Ryo ^a   Notomi, Takuya ^a   Nakamoto, Tetsuya ^a   Amagasa, Teruo ^a   Akiyoshi, Kazunari ^a   Noda, Masaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E4 RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CELL; BONE DEFECT; BONE REGENERATION; CALVARIA; CELL ACTIVATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FRACTURE HEALING; HYDROGEL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DISEASES; BONE MORPHOGENETIC PROTEIN 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED ICR; OSTEOGENESIS; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REGENERATION; SMAD4 PROTEIN; TISSUE SCAFFOLDS;

EID: 79953692404     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30151     Document Type: Article

References (33)

1. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988;85:9484-8. (Pubitemid 19027155)
2. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990;87: 2220-4.
3. Carreon LY, Glassman SD, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion in patients over 60 years of age: a cost-utility study. Spine 2009;34:238-43.
4. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008;62:ONS423-31.
5. Yang RS, Liu TK, Lin-Shiau SY. Increased bone growth by local prostaglandin E2 in rats. Calcif Tissue Int 1993;52:57-61.
6. Chase LR, Aurbach GD. The effect of parathyroid hormone on the concentration of adenosine 3′,5′-monophosphate in skeletal tissue in vitro. J Biol Chem 1970;245:1520-6.
7. Raisz LG, Pilbeam CC, Fall PM. Prostaglandins: mechanisms of action and regulation of production in bone. Osteoporos Int 1993;3 Suppl 1:136-40. (Pubitemid 23099913)
8. Suponitzky I, Weinreb M. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 1998;156:51-7. (Pubitemid 28049863)
9. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A 2002;99:4580-5. (Pubitemid 34286027)
10. Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, Fukushima M, et al. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 1996;137:1698-705. (Pubitemid 26133944)
11. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79: 1193-226. (Pubitemid 29473315)
12. Li M, Thompson DD, Paralkar VM. Prostaglandin E2 receptors in bone formation. Int Orthop 2007;31:767-72.
13. Tanaka M, Sakai A, Uchida S, Tanaka S, Nagashima M, Katayama T, et al. Prostaglandin E2, receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004;34:940-8. (Pubitemid 38749231)
14. Kato N, Hasegawa U, Morimoto N, Saita Y, Nakashima K, Ezura Y, et al. Nanogel-based delivery system enhances PGE2 effects on bone formation. J Cell Biochem 2007;101:1063-70. (Pubitemid 47253709)
15. Kato N, Kitahara K, Rittling SR, Nakashima K, Denhardt DT, Kurosawa H, et al. Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone. J Endocrinol 2007;193:171-82. (Pubitemid 46638543)
16. Nomura Y, Ikeda M, Yamaguchi N, Aoyama Y, Akiyoshi K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett 2003;553:271-6. (Pubitemid 37315616)
17. Akiyoshi K, Sasaki Y, Sunamoto J. Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Bioconjug Chem 1999;10:321-4. (Pubitemid 29243310)
18. Morimoto N, Endo T, Iwasaki Y, Akiyoshi K. Design of hybrid hydrogels with self-assembled nanogels as cross-linkers: interaction with proteins and chaperone-like activity. Biomacromolecules 2005;6:1829-34. (Pubitemid 41052171)
19. Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, Shiraishi T, et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 2008;99:601-7. (Pubitemid 351228580)
20. Ayame H, Morimoto N, Akiyoshi K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem 2008; 19:882-90. (Pubitemid 351614544)
21. Kofron MD, Laurencin CT. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev 2006;58:555-76. (Pubitemid 43928172)
22. Hayashi C, Hasegawa U, Saita Y, Hemmi H, Hayata T, Nakashima K, et al. Osteoblastic bone formation is induced by using nanogelcrosslinking hydrogel as novel scaffold for bone growth factor. J Cell Physiol 2009;220:1-7.
23. Morinobu M, Nakamoto T, Hino K, Tsuji K, Shen ZJ, Nakashima K, et al. The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic proteininduced bone formation. J Exp Med 2005;201:961-70. (Pubitemid 40524465)
24. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J 2009;28:2028-41.
25. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000;141: 1554-9. (Pubitemid 32269125)
26. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, et al. Resistance to unloading-induced threedimensional bone loss in osteopontin-deficient mice. J Bone Miner Res 2002;17:661-7. (Pubitemid 34246641)
27. Von Bubnoff A, Peiffer DA, Blitz IL, Hayata T, Ogata S, Zeng Q, et al. Phylogenetic footprinting and genome scanning identify vertebrate BMP response elements and new target genes. Dev Biol 2005;281:210-26. (Pubitemid 40719148)
28. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibulofacial nonunions. Clin Orthop Relat Res 1986;Apr(205):299-308. (Pubitemid 16011282)
29. Toyoda H, Terai H, Sasaoka R, Oda K, Takaoka K. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone 2005;37: 555-62. (Pubitemid 41317328)
30. Nakagawa K, Imai Y, Ohta Y, Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007;41:543-8. (Pubitemid 47385438)
31. Irie K, Alpaslan C, Takahaski K, Kondo Y, Izumi N, Sukakura Y, et al. Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2). J Bone Miner Metab 2003;21:363-9. (Pubitemid 38017692)
32. Flanagan AM, Chambers TJ. Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology 1992;130: 443-8.
33. Salari P, Abdollahi M. Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflamm Allergy Drug Targets 2009;8:169-75.